On 3 JUNE BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced the completion of an underwritten public offering of 11,500,000 shares of its common stock, including 1,500,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. All of the shares were offered at a price to the public of $10.00 per share. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) weekly performance is 15.60%. On last trading day company shares ended up $11.71. Analysts mean target price for the company is $17.00. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) distance from 50-day simple moving average (SMA50) is 28.34%.
22nd Century Group Inc (NYSEMKT: XXII) said it has continued on ahead, behaving as expected, punching through its key ceilings and solidifying the bullishness it was hinting at late last month. 22nd Century Group Inc (NYSEMKT: XXII) ended the day on $3.57. XXII its return on assets is -468.20%. 22nd Century Group Inc (NYSEMKT: XXII) quarterly performance is -37.80%.
On 2 JUNE Atossa Genetics Inc (NASDAQ:ATOS) announced that a presentation will be made at the 2014 American Society of Clinical Oncology (ASCO) Conference at McCormick Place, Chicago, Illinois, involving technology that has been licensed to Atossa by A5 Genetics KFT, Corporation. Atossa Genetics Inc (NASDAQ:ATOS) shares moved up 3.80% in last trading session and was closed at $1.64, while trading in range of $1.58 – $1.71. Atossa Genetics Inc (NASDAQ:ATOS) year to date (YTD) performance is -29.31%.
On 6 JUNE IsoRay, Inc. (NYSEMKT: ISR) reported third quarter EPS of ($0.05), $0.02 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.13 million versus the consensus estimate of $1.13 million. IsoRay, Inc. (NYSEMKT: ISR) ended the last trading day at $2.62. Company weekly volatility is calculated as 8.66% and price to cash ratio as 32.38. IsoRay, Inc. (NYSEMKT: ISR) showed a positive weekly performance of 12.93%.
Orexigen Therapeutics, Inc. (NASDAQ:OREX)said its application for the approval of the drug includes safety and cardiovascular dataset obtained from a trial, called Light Study, which was conducted on 8,900 individuals. Orexigen Therapeutics, Inc. (NASDAQ:OREX) weekly performance is -5.07%. On last trading day company shares ended up $5.81. Analysts mean target price for the company is $11.63. Orexigen Therapeutics, Inc. (NASDAQ:OREX) distance from 50-day simple moving average (SMA50) is 0.76%.